275 related articles for article (PubMed ID: 26068566)
41. Pediatric fatality review of the 2013 National Poison Database System (NPDS): focus on intent.
Lowry JA; Fine JS; Calello DP; Marcus SM
Clin Toxicol (Phila); 2015 Feb; 53(2):79-81. PubMed ID: 25567685
[No Abstract] [Full Text] [Related]
42. Differential physiological and behavioral cues observed in individuals smoking botanical marijuana versus synthetic cannabinoid drugs.
Chase PB; Hawkins J; Mosier J; Jimenez E; Boesen K; Logan BK; Walter FG
Clin Toxicol (Phila); 2016; 54(1):14-9. PubMed ID: 26653952
[TBL] [Abstract][Full Text] [Related]
43. Using Web searches to track interest in synthetic cannabinoids (a/k/a 'herbal incense').
Curtis B; Alanis-Hirsch K; Kaynak Ö; Cacciola J; Meyers K; McLellan AT
Drug Alcohol Rev; 2015 Jan; 34(1):105-8. PubMed ID: 25196534
[TBL] [Abstract][Full Text] [Related]
44. Clinical and analytical experience of the National Poison Control Centre with synthetic cannabinoids.
Vučinić S; Kilibarda V; Đorđević S; Đorđević D; Perković-Vukčević N; Vuković-Ercegović G; Antonijević B; Ćurčić M; Antonijević E; Brajković G
Arh Hig Rada Toksikol; 2018 Jun; 69(2):178-185. PubMed ID: 29990297
[TBL] [Abstract][Full Text] [Related]
45. [Spice drugs: cannabinoids as a new designer drugs].
Mustata C; Torrens M; Pardo R; Pérez C; ; Farré M
Adicciones; 2009; 21(3):181-6. PubMed ID: 19718488
[TBL] [Abstract][Full Text] [Related]
46. Initial impact of toll-free access on poison center call volume.
Krenzelok EP; Mrvos R
Vet Hum Toxicol; 2003 Dec; 45(6):325-7. PubMed ID: 14640488
[TBL] [Abstract][Full Text] [Related]
47. Characteristics and Treatment of Patients with Clinical Illness Due to Synthetic Cannabinoid Inhalation Reported by Medical Toxicologists: A ToxIC Database Study.
Monte AA; Calello DP; Gerona RR; Hamad E; Campleman SL; Brent J; Wax P; Carlson RG;
J Med Toxicol; 2017 Jun; 13(2):146-152. PubMed ID: 28397128
[TBL] [Abstract][Full Text] [Related]
48. Severe illness associated with reported use of synthetic cannabinoids: a public health investigation (Mississippi, 2015).
Kasper AM; Ridpath AD; Gerona RR; Cox R; Galli R; Kyle PB; Parker C; Arnold JK; Chatham-Stephens K; Morrison MA; Olayinka O; Preacely N; Kieszak SM; Martin C; Schier JG; Wolkin A; Byers P; Dobbs T
Clin Toxicol (Phila); 2019 Jan; 57(1):10-18. PubMed ID: 29989463
[TBL] [Abstract][Full Text] [Related]
49. Synthetic cannabinoid use in a nationally representative sample of US high school seniors.
Palamar JJ; Acosta P
Drug Alcohol Depend; 2015 Apr; 149():194-202. PubMed ID: 25736618
[TBL] [Abstract][Full Text] [Related]
50. [The illegal synthetic cannabinoid drug market in Israel - evolution and new challenges].
Shapira B; Poperno A; Berkovitz R
Harefuah; 2016 Sep; 155(9):526-530. PubMed ID: 28530077
[TBL] [Abstract][Full Text] [Related]
51. Psyclones: a roller coaster of life? Hidden synthetic cannabinoids and stimulants in apparently harmless products.
Santacroce R; Corazza O; Martinotti G; Bersani FS; Valeriani G; Di Giannantonio M
Hum Psychopharmacol; 2015 Jul; 30(4):265-71. PubMed ID: 26216561
[TBL] [Abstract][Full Text] [Related]
52. Synthetic cannabinoid use in New Zealand: a recent rebound.
Schep LJ; Slaughter RJ; Temple WA; Lambie BS; Gee P; Watts M; Gresham C
N Z Med J; 2012 Oct; 125(1364):114-6. PubMed ID: 23242407
[No Abstract] [Full Text] [Related]
53. Epidemiological trends in electronic cigarette exposures reported to U.S. Poison Centers.
Vakkalanka JP; Hardison LS; Holstege CP
Clin Toxicol (Phila); 2014 Jun; 52(5):542-8. PubMed ID: 24792781
[TBL] [Abstract][Full Text] [Related]
54. Synthetic cannabinoid and cathinone use among US soldiers.
Berry-Cabán CS; Kleinschmidt PE; Rao DS; Jenkins J
US Army Med Dep J; 2012; ():19-24. PubMed ID: 23007932
[TBL] [Abstract][Full Text] [Related]
55. Synthetic cannabinoids: the dangers of spicing it up.
Salani DA; Zdanowicz MM
J Psychosoc Nurs Ment Health Serv; 2015 May; 53(5):36-43. PubMed ID: 25974923
[TBL] [Abstract][Full Text] [Related]
56. Synthetic Cannabinoid Abuse in Adolescents: A Case Series.
Besli GE; Ikiz MA; Yildirim S; Saltik S
J Emerg Med; 2015 Nov; 49(5):644-50. PubMed ID: 26293411
[TBL] [Abstract][Full Text] [Related]
57. A multicenter retrospective survey of poisoning after consumption of products containing synthetic chemicals in Japan.
Kamijo Y; Takai M; Fujita Y; Hirose Y; Iwasaki Y; Ishihara S; Yokoyama T; Yagi K; Sakamoto T
Intern Med; 2014; 53(21):2439-45. PubMed ID: 25366001
[TBL] [Abstract][Full Text] [Related]
58. NBOMe designer drug exposures reported to Texas poison centers.
Forrester MB
J Addict Dis; 2014; 33(3):196-201. PubMed ID: 25115175
[TBL] [Abstract][Full Text] [Related]
59. Clinical and financial implications of emergency department visits for synthetic marijuana.
Rowley E; Benson D; Tiffee A; Hockensmith A; Zeng H; Jones GN; Musso MW
Am J Emerg Med; 2017 Oct; 35(10):1506-1509. PubMed ID: 28457767
[TBL] [Abstract][Full Text] [Related]
60. The Changing Face of Synthetic Cannabinoids in Texas.
Maxwell JC
J Psychoactive Drugs; 2018; 50(4):281-286. PubMed ID: 30321129
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
